Frederic Triebel
33Patents
13h-index
20Co-inventors
81Inventor score
Filing activity: Feb 24, 1995 → Oct 16, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6143273A | Therapeutic composition containing antibodies to soluble polypeptide fractions of LAG-3 protein | Chemistry; Metallurgy | 60 | Expired |
| US5976877A | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses | Emerging Cross-Sectional Technologies | 51 | Expired |
| US5773578A | Proteins produced by human lymphocytes, DNA sequence encoding these proteins and their pharmaceutical and biological use | Emerging Cross-Sectional Technologies | 50 | Expired |
| US6482925B1 | Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants | Chemistry; Metallurgy | 43 | Expired |
| US5874250A | DNA encoding for a protein containing the extracellular domain of lymphocyte activation gene 3 | Emerging Cross-Sectional Technologies | 42 | Expired |
| USRE38313E1 | Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies | General | 41 | Expired |
| US9244059B2 | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease | Physics | 29 | Active |
| US5955300A | Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies | Chemistry; Metallurgy | 23 | Expired |
| US6855802B1 | Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy | Chemistry; Metallurgy | 23 | Expired |
| US6410509B1 | Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment | Emerging Cross-Sectional Technologies | 19 | Expired |
| US5700907A | Nucleotide sequences coding for variable regions of .beta. chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses | Human Necessities | 18 | Expired |
| US9908936B2 | Antibody molecules to LAG-3 and uses thereof | Physics | 17 | Active |
| US6596536B1 | Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses | Emerging Cross-Sectional Technologies | 16 | Expired |
| US6114516A | Nucleotide sequences coding for variable regions of the .alpha.chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic muses | Emerging Cross-Sectional Technologies | 11 | Expired |
| US5817511A | Nucleotide sequence coding for variable regions of the .alpha. chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses | Emerging Cross-Sectional Technologies | 11 | Expired |
| US5798231A | Nucleotide sequences for .alpha. chain variable regions in human lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses | Emerging Cross-Sectional Technologies | 10 | Expired |
| US5830758A | Isolated V.beta. TCR antibodies | Human Necessities | 10 | Expired |
| US7294712B2 | Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses | Human Necessities | 10 | Expired |
| US7109026B2 | Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment | Emerging Cross-Sectional Technologies | 8 | Expired |
| US6875844B1 | Peptide compounds derived from a shifted ORF of the iCE gene | Chemistry; Metallurgy | 8 | Expired |
| US10711060B2 | Antibody molecules to LAG-3 and uses thereof | Physics | 7 | Active |
| US9579382B2 | Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response | Chemistry; Metallurgy | 5 | Active |
| US8425897B2 | Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use | Human Necessities | 5 | Active |
| US10232038B2 | Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response | Chemistry; Metallurgy | 2 | Active |
| US10940181B2 | Combined preparations for the treatment of cancer or infection | Emerging Cross-Sectional Technologies | 2 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.